Revolutionizing Chemotherapy Delivery for
Better Patient Outcomes

The Problem

Cancers Prevalence

1 out of 5 people develop cancer during their life

Treatments are hurting patients

90% of patients undergoing chemotherapy report heavy side-effects

Cost of treating side-effects

Cost associated with treatment of side-effects is greater than 20 000$ yearly per patient

Antibody therapeutics as a solution

Antibodies have emerged as a key path to better cancer therapies. In the ADC market alone this resulted in 8 over $1b USD deals in 2024

reduce the harm patients endure during treatment while increasing therapeutic success

Imagine a world

where you can undergo chemotherapy treatment without
losing your hair and poisoning your body

AbsTech's Mission

What sets AbsTech apart

Strategic Partnerships

We provide pharmaceutical companies with opportunities to enhance the therapeutic index of their existing treatments, unlocking their full potential

Better Outcomes for Patients

Our proprietary system reduces chemotherapy toxicity maintaining effectiveness, and significantly
improving patients' quality of life

Efficiency and Cost-Effectiveness
Designed for faster and more economical development, our platform is versatile and can be applied to a wide range of treatments for solid tumours

AbsTech technology can reduce the toxicity of known chemotherapeutics by orders of magnitude while maintaining their efficacy

Our in-cell results show we can minimize side effects and can function with various cancer types and therapeutic agents, paving the way for a broad range of applications

Our proof of concept

Today...

Our solution

AbsTech's Team

Benjamin Weiser

Expert in AI-driven computational chemistry with startup experience optimizing drug discovery. Ben’s business sense and expertise in artificial intelligence accelerate our research and focus on high-impact projects

Simon Beaudoin, PhD

Assistant Professor at UdeS, biochemistry researcher, serial inventor, and entrepreneur with extensive experience guiding therapies through clinical phases. Simon’s expertise in biochemistry is foundational to our team and ensures that our projects translate into successful therapies

Adam Dufour

Specialist in antibody-based therapies and pharmaceutical chemistry, with proven experience in developing early-stage biotech companies. Adam’s insights help us strategically target chemotherapies that can benefit the most from our technology

Contact us

If you are interested in knowing more about collaborating or investing in AbsTech, reach out!